OncoMatch/Clinical Trials/NCT06635330
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Is NCT06635330 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies anti-CD19 CAR T cell therapy for relapse/refractory b-cell acute lymphoblastic leukemia.
Treatment: anti-CD19 CAR T cell therapy — The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). The main questions it aims to answer are as following: 1. What is the percentage of patients with overall remission rate (ORR) of complete response (CR) or complete remission with incomplete blood count recovery (CRi)? 2. What is the rate of Event-free survival at first month and 2-3 months after intervention? 3. What is the rate of Overall survival at first month and at 3 months after the intervention?
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive
Prior therapy
Cannot have received: anti-CD19 therapy
History of Anti-CD19 ... therapy
Cannot have received: anti-CD20 therapy
History of Anti-CD20 therapy
Cannot have received: donor lymphocyte injection or other cell therapy methods
Exception: within the last 30 days
Donor lymphocyte injection or other cell therapy methods within the last 30 days
Cannot have received: radiation therapy
Exception: within last 14 days
Radiation therapy within last 14 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify